A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (CEMIPLIMAB; ANTI-PD-1 Antibody) and Ipilimumab (ANTI-CTLA-4 Antibody) In the Second-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%
